LOL, you're probably right.
The thing acts like real sht, you can't deny that.
This is one of these stocks I went back on a one big rule I have: don't get involved with garbage again.
It was a loser back when they failed their trial back in '09?, or '10? I got back involved because I looked at their pipeline and clearly one would think that many drugs would be worth more than $130 mill market cap considering some reallll pig trash-heaps (SNSS et al) have market caps comparable or even more than ARRY's current.
Something clearly isn't right with the company, and it probably has more to do with financing the company through Phase 3, than it does their R&D; but then again, they already failed one trial with their key drug.
Market Data 
Markets 
AI
